Latest news

Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CAIX-Targeted Radiopharmaceutical Program

Debiopharm Applies Extended-Release Formulation Expertise To Reduce Treatment Frequency Burden For Acromegaly & GEP-NET Patients

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor